Mendus AB · OMXSTO:IMMU

Mendus AB — Q3 2026 Earnings Presentation

29 slides from Mendus AB's earnings presentation, Nov 11, 2026

  1. Slide 1: Report on the third quarter 2026

    Changing the course of cancer treatment Report on the third quarter 2026

  2. Slide 2: Significant events Q3 2026

    Significant events Q3 2026 » Net sales for the period amounted to KSEK - (-) » Mendus drew SEK 16.5 million under the second tranche of the Fenja Capital II A/S loan facility and extended the » Result for the period amounted to KSEK -22,685 (-19,014). maturity date to April 2027, securing the Compan

  3. Slide 3: CEO Comment: Transforming immunotherapy for myeloid blood cancers

    CEO Comment Transforming immunotherapy for myeloid blood cancers Growing evidence from completed and ongoing trials indicates that vididencel stimulates the immune system in a unique way, leading to broad tumor-directed immune responses and improved immune competence. This may be the key to resolvin

  4. Slide 4: CEO comment continued: SAHMRI collaboration and VITAL-TFR2

    rienced a failed TFR attempt due to relapse. To support With gratitude towards our clinical collaborators and the trial, Mendus entered a collaboration with the South patients participating, we look forward to keeping our Australian Health and Medical Research Institute (SAHMRI), stakeholders inform

  5. Slide 5: Mendus in short – Q3 2026

    Mendus in short – Q3 2026 Mendus is a clinical-stage biopharmaceutical company dedicated to transforming immunotherapy for myeloid blood cancers. “Preserving health and quality of life” In today’s cancer therapy landscape, many cancer patients Vididencel is manufactured from a proprietary cell line

  6. Slide 6: Developing vididencel across the first-line AML treatment landscape

    Mendus is developing vididencel across the first-line AML treatment landscape. The randomized controlled Phase 2b CADENCE trial combines vididencel with oral azacitidine (Aza) following intensive chemotherapy, independent of MRD status. The trial is led by Prof. Dr. Andrew Wei (Peter MacCallum Cance

  7. Slide 7: Clinical Strategy Positions Vididencel Across AML and CML

    prising dendritic cells derived from healthy donor material. Preclinical pipeline Administered directly into the tumor, ilixadencel is designed As part of the collaboration with UMCG, Mendus has to stimulate local inflammation and enhance the presen- developed improved methods to expand tumor-infilt

  8. Slide 8: Q&A with Mendus COO Hans Preusting

    Interview Q&A with Mendus COO Hans Preusting Hans Preusting (PhD, MBA) joined Mendus’ executive management team as Chief Operating Officer (COO) in October. He has been involved with the company since 2018, initially as a consultant supporting manufacturing activities and subsequently as a board mem

  9. Slide 9: Interview

    Interview I’ve been part of Mendus’ journey for almost a decade: material. Vididencel, on the other hand, is derived from as a consultant, board member, and now as part of the a proprietary cell line and carries its own antigens. The executive management team. I’ve seen the evolution up final produc

  10. Slide 10: Financial information: The Group

    Financial information The Group Revenue January–September. Result for the period amounted to KSEK -22,685 (-19,014) for the third quarter and KSEK No revenue was recognised in the third quarter – (–) or -65,084 (-72,183) for the period January–September. The in the period January–September – (–). Ot

  11. Slide 11: Financial information: Parent Company

    Financial information Parent Company Mendus AB Revenue month period. Result for the period amounted to KSEK -6,814 (-8,731) for the third quarter and KSEK -17,235 No revenue was recognised in the third quarter – (–) or in the (-24,363) for the nine-month period. Net financial items nine-month period

  12. Slide 12: Other Disclosures

    Other Disclosures Share-based incentive programmes Employees The purpose of share-based incentive programmes is As of 30 September 2026, the Group had 18 (29) employ- to promote the long-term interests of the Company by ees, of whom 12 (18) were women and 6 (11) were men. motivating and rewarding se

  13. Slide 13: Review report

    Review report To the Board of Directors of Mendus AB (publ) Corp. id. 556629-1786 Introduction We have reviewed the condensed interim financial information (interim report) of Mendus AB (publ) as of 30 September 2026 and the nine-month period then ended. The Board of Directors and the Managing Direc

  14. Slide 14: Financial Reports: The Group

    FINANCIAL REPORTS THE GROUP

  15. Slide 15: Consolidated income statement

    Consolidated income statement 2026 2025 2026 2025 2025 Amounts in KSEK Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Revenue – – – – – Total revenue – – – – – OPERATING EXPENSES Administration expenses -9,126 -9,514 -27,985 -28,335 -35,195 Research and development expenses -13,261 -12,979 -45,00

  16. Slide 16: Consolidated balance sheet statement

    Consolidated balance sheet statement Amounts in KSEK 30/09/2026 30/09/2025 31/12/2025 ASSETS NON-CURRENT ASSETS Goodwill 108,350 108,350 108,350 Technology 424,091 424,091 424,091 Right-of-use assets 15,614 18,119 17,023 Equipment 2,766 5,799 4,971 Other long term receivables 1 810 795 Total non-cur

  17. Slide 17: Consolidated statement of changes in equity

    Consolidated statement of changes in equity Attributable to owners of Mendus AB (publ) Retained Additional earnings incl. Share paid-in profit/loss for Amounts in KSEK capital capital Reserves the period Total Opening shareholders’ equity 01/01/2026 62,585 1,496,813 -3,835 -970,497 585,065 Profit/lo

  18. Slide 18: Consolidated statement of cash flows

    Consolidated statement of cash flows 2026 2025 2026 2025 2025 Amounts in KSEK Note Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec OPERATING ACTIVITIES Profit/loss before tax -22,685 -19,014 -65,084 -72,183 -113,258 Adjustment for items not included in cash flow 9 5,610 2,698 13,852 8,562 13,991 I

  19. Slide 19: Financial Reports: Parent Company

    FINANCIAL REPORTS PARENT COMPANY

  20. Slide 20: Parent Company income statement

    Parent Company income statement 2026 2025 2026 2025 2025 Amounts in KSEK Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Revenue – – – – – Total revenue – – – – – OPERATING EXPENSES Administration expenses -6,111 -6,242 -17,967 -18,856 -24,074 Research and development expenses -1,903 -4,304 -6,639

  21. Slide 21: Parent Company balance sheet

    Parent Company balance sheet Amounts in KSEK 30/09/2026 30/09/2025 31/12/2025 ASSETS Financial assets Shares/Participations in Group companies 1,024,511 967,821 985,834 Other long term securities 1 1 1 Other long term receivables – 587 577 Total financial assets 1,024,512 968,409 986,412 Total fixed

  22. Slide 22: Parent Company statement of changes in equity

    Parent Company statement of changes in equity Retained earnings incl. Share Share premium profit/loss for Amounts in KSEK capital reserve the period Total Opening shareholders’ equity 01/01/2026 62,585 1,782,001 -797,498 1,047,088 Profit/loss for the period – – -17,235 -17,235 Total comprehensive in

  23. Slide 23: Parent Company cash flow statement

    Parent Company cash flow statement 2026 2025 2026 2025 2025 Amounts in KSEK Note Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Operating activities Profit/loss before tax -6,814 -8,731 -17,235 -24,363 -27,678 Adjustment for items not included in cash flow 9 4,822 1,008 10,022 3,933 6,881 Interes

  24. Slide 24: Notes

    Notes Note 1 – General information revenue and is not expected to do so in the short term. The Company’s product candidates depend on research Mendus AB (publ) (hereinafter "Mendus"), registration and development and may be delayed and/or result in number 556629-1786, is a Swedish public company­ hi

  25. Slide 25: Notes: related parties, financial instruments, subsequent events

    purchases amounted to KSEK -404 (-21). No further related ­ rincipal investigator of the ADVANCE II and VITAL-CML p party transactions have taken place during the year. All trials, presented “Dendritic cell immunotherapy in myeloid transactions with related parties are conducted on an arm’s leukemia

  26. Slide 26: Key performance measurements

    Key performance measurements The company presents in this report certain key performance measures, including two measures that are not defined under IFRS, namely expenses relating to research and development/operating expenses and equity ratio. These financial performance measures should not be view

  27. Slide 27: Definitions and reconciliation of alternative performance measurements

    Definitions and reconciliation of alternative performance measurements Alternative performance measurements Definition Justification Equity ratio Total shareholders’ equity divided by The key ratio provides useful information of the company’s total assets capital structure. Research & development Re

  28. Slide 28: Financial Calendar and contact information

    Financial Calendar » Publication of Year-end Report 2026 February 11, 2027 » Publication of the Annual Report 2026 April 20, 2027 » Annual General Meeting 2027 May 11, 2027 For further information, please contact: Erik Manting, CEO, Mendus Telephone: +46 (0)8 732 8400 E-mail: ir@mendus.com Lotta Fer

  29. Slide 29: www.mendus.com

    www.mendus.com eccce eeoce eecce eeccee

Mendus — Q3 2026 Earnings Presentation on 6ix